AMICUS AI
Citation Codes
Equivalent Citations
citation codes
Docket Number
Advocates
Judges
Are you a practicing lawyer?
Enhance your digital presence and reach by creating a Casemine profile.
Upload pleading to use the new AI search
Cites
Cited by
Citation Codes
Equivalent Citations
citation codes

FULFILLIUM, INC., Plaintiff and Appellant, v. INTERSECT PARTNERS, LLC, Defendant and Respondent.

GOETHALS, J.

NOT TO BE PUBLISHED

Appeal from a judgment of the Superior Court of Orange County No. 30-2018-01017328, Theodore R. Howard, Judge. Affirmed.

Law Offices of Seth W. Wiener and Seth W. Wiener for Plaintiff and Appellant.

Wesierski &Zurek, Christopher P. Wesierski, Abe G. Salen and Claudia Mourad for Defendant and Respondent.

OPINION

GOETHALS, J.

Fulfillium, Inc., (Fulfillium) appeals from the trial court's entry of judgment on its sole cause of action for trade secrets misappropriation after the court granted summary judgment in favor of Intersect Partners, LLC, (Intersect) on statute of limitations grounds. The trial court found that the date on which the relevant federal regulatory agency gave a third party premarket approval (PMA) for an intragastric device was the date the limitations period began to run. As we explain, Fulfillium presented no evidence in opposing summary judgment that the PMA was nonpublic information, nor did it assert relation back or equitable tolling theories in opposition to summary judgment; its other contentions on appeal are also without merit. We therefore affirm the trial court's ruling and entry of judgment.

FACTUAL AND PROCEDURAL BACKGROUND

In April 2017, Fulfillium asserted causes of action in a Delaware federal district court against ReShape Medical, Inc., (ReShape Medical) for trade secret misappropriation and patent infringement. The district court granted defendant's motion to dismiss the trade secret claim, with leave to amend, and in November 2017 transferred the case to the United States District Court for the Central District of California.

There, in July 2018, the district court dismissed the patent infringement claim without prejudice, apparently leaving only a state law trade secrets claim. On August 10, 2018, the district court dismissed the lawsuit altogether for lack of subject matter jurisdiction in the absence of any pending federal claims.

Meanwhile, after the district court dismissed Fulfillium's patent infringement claim in July 2018, instead of filing an amended complaint in that action to reassert the claim, Fulfillium filed a new federal court action on July 20, 2018, against ReShape Medical and a related entity, ReShape Life Sciences, Inc. (ReShape Life), in the central district alleging patent infringement.

On August 15, 2018, five days after the dismissal of its first federal court action against ReShape Medical, Fulfillium filed an amended complaint in its second federal court action. The amended complaint named Intersect as a defendant for the first time. The amended complaint asserted trade secret misappropriation against Intersect, ReShape Medical, and a third defendant, SV Health Investors, LLC (SV Health). It also reasserted the patent infringement claims against ReShape Medical and ReShape Life.

Intersect and SV Health won dismissals when the district court found the trade secrets claim was barred by Civil Code section 3426.6's three-year statute of limitations. The district court noted Fulfillium had submitted a declaration in the first federal action stating that its principal, Dr. Richard Chen, "learned" in the summer of 2014 "from ReShape's website that ReShape had submitted an FDA [Food and Drug Administration] application for pre-market approval." At that time, according to Chen, he '"started investigating the ReShape clinical study"' and claimed he '"ultimately learned that ReShape had copied [m]y entire FDA playbook, including my clinical trial design and selection of principal investigator."'

All further undesignated statutory references are to the Civil Code.

The district court acknowledged defendants contended "the declaration proves indisputably that Chen became aware of his trade secret claims when [Fulfillium] started investigating the ReShape clinical trial in 2014." The district court also observed Fulfillium countered that, while Chen "became aware that ReShape was developing an important product, it was impossible to discern the nature of that product until it emerged from 'stealth mode' and received pre-market approval in 2015." Citing Fulfillium's original complaint, the district court found the PMA date was July 28, 2015.

Consequently, the district court denied ReShape Medical's motion to dismiss on statute of limitations grounds, but granted Intersect's and SV Health's similar motions. The court explained that in filing suit against ReShape Medical in the second federal action on July 20, 2018, Fulfillium's complaint fell within the three-year limitations window that "began to run when Chen received notice that ReShape had copied its trade secrets on July 28, 2015." Thus, "the claim against ReShape Medical is timely." In contrast, because Fulfillium did not name Intersect or SV Health in any capacity until August 15, 2018, "those claims are time-barred and thus dismissed, unless tolling applies."

The district court found that equitable tolling during pursuit of a remedy in another forum did not apply "when a case is filed successively in the same forum." The court also found the relation-back doctrine did not apply because Fulfillium did not "allege that it mistook either Defendant's identity in the original complaint." To the contrary, "SV Health was named repeatedly in the body of the complaint, but for some reason not named as a Defendant."

While the second federal action was pending, Fulfillium filed the separate state court action that is the subject of this appeal. Fulfillium filed the suit on September 7, 2018, alleging trade secret misappropriation against Intersect, Reshape Medical, and SV Health. Intersect filed a motion for summary judgment based on the three-year limitation period (§ 3426.6); the trial court ultimately granted the motion.

As noted in the trial court's summary judgment ruling, Fulfillium "settled with and subsequently dismissed ReShape LLC and SV Health LLC with prejudice" by the date of the ruling, such that Intersect was "[t]he only remaining defendant in the action ...." The court also noted in its ruling that Fulfillium "appealed the federal courts'" dismissals in its two actions in the Central District, apparently without success, as "[t]he parties in this [state] action stipulated to a stay while Plaintiff's federal appeals were pending."

The trial court explained its thinking in its written ruling: "Although Plaintiff [Fulfillium] disputes that the FDA's grant of ReShape's PMA application was 'publicly published,' (see Plaintiff's Separate Statement, No. 13)," Fulfillium offered "no evidence to support [its] contention." "As such," the trial court concluded, "Plaintiff has raised no triable issue of fact as to whether its misappropriation claim in connection with the ReShape device accrued by 7/28/2015." (Italics added.)

"It bears repeating," the trial court emphasized: "that Intersect's alleged misappropriation arises in connection with its alleged formation and management of ReShape, including ReShape's clinical trial(s) and pursuit of FDA PMA approval regarding the subject ReShape device."

Specifically, according to Fulfillium's first amended complaint, Intersect and a venture capital entity known as SV Life Sciences were part of the management team at ReShape Medical. According to Chen, in seeking funds to develop Fulfillium's intragastric medical device years earlier, he spoke with several individuals about his ideas, including a partner at SV Life Sciences sometime in 2005. Fulfillium did not obtain funding from SV Life Sciences; Intersect, however, incorporated a new medical device entity known as Abdominis in or around late 2005, and Abdominis changed its name to ReShape Medical in December 2006.

In its summary judgment moving papers, Intersect presented evidence that Chen became aware of ReShape Medical's efforts to develop an intragastric device as early as 2009. Intersect's evidence also suggested Chen knew in 2014 that ReShape Medical had completed the clinical trial for its device and applied for its FDA PMA, which prompted Chen to consult with Fulfillium's shareholders regarding his suspicions about theft of its intellectual property.

Against this backdrop, the trial court found that Fulfillium "has not offered evidence showing that Intersect's alleged misappropriation was separate from and/or subsequent to ReShape's alleged misappropriation. As such, the statute of limitations for such alleged misappropriation was not tolled simply by the fact that Plaintiff [Fulfillium] apparently did not investigate Intersect's involvement until several years after learning of the alleged misappropriation involving the subject ReShape device's clinical trial(s) and pursuit of FDA approval."

The trial court ruled that, as the party seeking to toll a limitations period, Fulfillium "bore a burden to exercise reasonable diligence, and/or to now offer evidence showing that [it] was prevented from exercising such diligence." In granting summary judgment against Fulfillium, the court found it "has not offered such evidence so as to toll the subject statute of limitations with respect to Intersect."

DISCUSSION

"A defendant moving for summary judgment bears the initial burden to show the plaintiff's action has no merit. [Citation.] The defendant can meet that burden by either showing the plaintiff cannot establish one or more elements of his or her cause of action or there is a complete defense to the claim." (Carlsen v. Koivumaki (2014) 227 Cal.App.4th 879, 889; Code Civ. Proc., § 437c, subd. (p)(2).) "The expiration of the applicable statute of limitations is one such complete defense." (Professional Collection Consultants v. Lauron (2017) 8 Cal.App.5th 958, 965.)

We review a grant of summary judgment de novo. (Eriksson v. Nunnink (2011) 191 Cal.App.4th 826, 848.) "'"[I]n practical effect, we assume the role of a trial court and apply the same rules and standards that govern a trial court's determination of a motion for summary [judgment]."'" (California Bank &Trust v. Lawlor (2013) 222 Cal.App.4th 625, 631.)

"The statute of limitations operates in an action as an affirmative defense." (Norgart v. Upjohn Co. (1999) 21 Cal.4th 383, 396.) Summary judgment based on an affirmative defense is proper if undisputed facts establish the defense. (Consumer Cause, Inc. v. SmileCare (2001) 91 Cal.App.4th 454, 468.) If the defendant meets its initial burden to show the existence of an affirmative defense, the burden shifts to the plaintiff to present evidence establishing a triable issue of material fact concerning at least one element of the affirmative defense. (Anderson v. Metalclad Insulation Corp. (1999) 72 Cal.App.4th 284, 290.) "[Although] resolution of the statute of limitations issue is normally a question of fact, where the uncontradicted facts . . . are susceptible of only one legitimate inference, summary judgment is proper." (Jolly v. Eli Lilly &Co. (1988) 44 Cal.3d 1103, 1112.)

Section 3426.6 is codified as part of the Uniform Trade Secrets Act (see § 3426) and provides the relevant limitations period: "An action for misappropriation must be brought within three years after the misappropriation is discovered or by the exercise of reasonable diligence should have been discovered." (§ 3426.6.)

The statute begins to run when the plaintiff has reason to be suspicious that a trade secret has been misappropriated, and a reasonable investigation would produce facts sufficient to confirm that suspicion. (Cypress Semiconductor Corp. v. Superior Court (2008) 163 Cal.App.4th 575, 586-587 (Cypress Semiconductor), citing Fox v. Ethicon Endo-Surgery, Inc. (2005) 35 Cal.4th 797, 807.) "[I]t is not necessary that the plaintiff be able to identify the person or persons causing the harm. Since the identity of the defendant is not an element of a cause of action, the failure to discover the identity of the defendant does not postpone accrual of the cause of action." (Id. at p. 587.) Once a reasonable suspicion of wrongdoing arises, "'it is clear that the plaintiff must go find the facts; [it] cannot wait for the facts to find [it].'" (Gabriel Technologies Corp. v. Qualcomm Inc. (2012) 857 F.Supp.2d 997, 1003 (Gabriel Technologies), quoting Jolly v. Eli Lilly &Co., supra, 44 Cal.3d at p. 1111.)

Fulfillium contends the trial court erred in finding its trade secret misappropriation claim "accrued by July 28, 2015, which was more than three years before the September 7, 2018 date of [its] state court complaint." The July 28, 2015 date was when ReShape Medical received FDA PMA for its intragastric device, which Fulfillium claims was based on stolen trade secrets.

On appeal, Fulfillium disputes the relevancy of the July date on two grounds. First, it provides a website citation by which it suggests that "the Federal Register containing the FDA's PMA for the Re[S]hape device was not filed until November 17, 2015," a date which-if Fulfillium had no suspicion of misappropriation until then-would have brought its September 2018 filing against Intersect within the limitations period. In a related contention, Fulfillium concedes the FDA posted the PMA on the Internet, but argues the summary judgment record "provides no indication of the date it was first posted on the FDA's website."

Second, Fulfillium also argues that "even if the pre-market approval of ReShape's device was in some sense widely published in July 2015 (though there is no evidence of this), that would not eliminate the factual dispute about whether Fulfillium knew or should have discovered Intersect's misappropriation on that date. Just because information is publicly available does not mean everyone is on actual or constructive notice of that information." (Italics added.)

These arguments are not persuasive for several reasons. First, the trial court did not find that Fulfillium must have discovered misappropriation of its trade secrets on a particular date, but rather that it knew or should have known of the misappropriation by the July 28, 2015 date that Fulfillium referenced in its pleadings. Fulfillium identified that date as marking the end of an alleged '"stealth mode"' period for those who stole its trade secrets. Paragraph 43 of Fulfillium's amended complaint stated: "As is typical for a medical start-up company, ReShape Medical, Inc. operated in 'stealth mode' during development. ReShape Medical, Inc. started pivotal clinical trials in 2012 and applied for FDA approval in 2014. The FDA granted Pre-Marketing Approval to the ReShape Duo' device and treatment method on July 28, 2015." (Italics added.)

The reference to the date and grant of approval reasonably led the trial court-and the district court based on similar pleadings-to infer Fulfillium was aware of the PMA on that date. Specifically, the trial court read Fulfillium's paragraph 43 as "alleg[ing] that it was aware that ReShape Medical Inc. was given pre-market approval . . . on July 28, 2015." It makes little sense to suppose Fulfillium referenced FDA approval and the date thereof in paragraph 43, but did not intend to convey that it was aware of both on the date specified. This is particularly true when Fulfillium elsewhere gave an express disclaimer of specific knowledge; Fulfillium stated in paragraph 43, after referencing the FDA's PMA and date: "At that time, Fulfillium did not know of Intersect Partners' involvement in ReShape." (Italics added.)

Notably, the inference of knowledge in the district court proceedings was inescapable. There, Fulfillium alleged in its complaint that "[w]hen ReShape Medical, Inc. emerged from stealth mode," which Fulfillium similarly identified in the complaint as July 28, 2015, "Dr. Chen learned that ReShape Medical, Inc. had copied his trade secrets, including his entire clinical trial 'playbook.'" (Italics added.)

This disclaimer regarding Intersect's identity was irrelevant, however. "[T]he law is clear that 'once the plaintiff has a suspicion of wrongdoing, and therefore an incentive to sue,'" the clock begins to tick for the plaintiff to "'decide whether to file suit or sit on [its] rights.'" (Gabriel Technologies, supra, 857 F.Supp.2d at p. 1003.) As the court explained in Cypress Semiconductor, ""'[T]he rationale for distinguishing between ignorance" of the defendant and "ignorance" of the cause of action itself "appears to be premised on the commonsense assumption that once the plaintiff is aware of" the latter, he "normally" has "sufficient opportunity," within the "applicable limitations period," "to discover the identity" of the former."' (Cypress Semiconductor, supra, 163 Cal.App.4th at p. 587.)

Second and related, Intersect presented substantial evidence in moving for summary judgment that Fulfillium strongly suspected-indeed categorically concluded- well before the PMA date that ReShape Medical misappropriated its trade secrets. Intersect cited in its moving papers e-mails Chen sent Fulfillium's investors a year earlier, in July 2014, which said "[t]he company that stole our idea has now filed for a PMA," "the company that stole Fulfillium's idea has now filed for a PMA," and claimed "[t]hey pretty much followed what I outlined for them" in confidential meetings conducted when he had been seeking funding. Several of the e-mails included Chen's unequivocal assertions that "[t]hey followed the roadmap I gave them" and "they did not do it independently" but instead "used our playbook."

In light of the foregoing, we conclude in our de novo review that Intersect met its initial burden in moving for summary judgment to establish that the limitations period began to run at least by July 28, 2015, if not as much as a full year earlier.

"A defendant moving for summary judgment based on the affirmative defense of the statute of limitations carries its burden by presenting evidence establishing that the plaintiff's claim is time-barred." (Genisman v. Carley (2018) 29 Cal.App.5th 45, 49.) "'It then falls to plaintiff[ ] to counter with evidence creating a dispute about a fact relevant to that defense.' [Citation.] That is, the plaintiff must submit evidence that would allow a 'reasonable trier of fact [to] find in plaintiff['s] favor on the statute of limitations issue.'" (Ibid.)

The July 2014 e-mails showed Fulfillium believed ReShape Medical stole its trade secrets as of that date. The e-mails also pointed to a reasonable foundation for Chen's suspicions, including that he knew enough about ReShape Medical's "gastric balloon" to believe it was based on stolen ideas he had "outlined" earlier in confidential presentations seeking funding, and the "roadmap" and "playbook" he gave to prospective investors. The e-mails further identified what appears to be a press release from ReShape Medical's website, which the trier of fact could deduce was at least a partial source for Chen's conclusion his ideas were stolen. Thus, the e-mails supported a trigger date for the limitations period beginning in July 2014 when the plaintiff "had any reason to suspect" that a trade secret had been misappropriated, and a reasonable investigation would produce facts sufficient to confirm that suspicion. (Cypress Semiconductor, supra, 163 Cal.App.4th at pp. 586-587, citing Fox v. Ethicon Endo-Surgery, Inc., supra, 35 Cal.4th at p. 807.)

Even assuming arguendo that was not enough, paragraph 43 of Fulfillium's complaint expressly admitted that, by July 28, 2015, Fulfillium "knew" that at least two individuals guiding ReShape Medical (George Wallace and Andrew Cragg) had prior association with a venture capital entity, SV Life Sciences, and that Chen disclosed his ideas to them before 2014. While tracing who stole the ideas was not, as discussed, necessary for Fulfillium's misappropriation claim to accrue, it adds to the conclusion the basis for the claim arose by July 28, 2015.

In the face of this evidence supporting commencement of the limitations period no later than July 28, 2015, it was incumbent upon Fulfillium in opposing summary judgment to respond with evidence creating a triable issue of fact. Once the burden shifts to a plaintiff opposing summary judgment, "the plaintiff must produce substantial responsive evidence sufficient to establish a triable issue of material fact on the merits of the defendant's showing." (Sangster v. Paetkau (1998) 68 Cal.App.4th 151, 162-163; Code Civ. Proc., § 437c, subd. (p)(2).)

Fulfillium failed to do so. As the trial court found, "Plaintiff offer[ed] no evidence to support [its] contention" disputing "that the FDA's grant of ReShape's PMA application was 'publicly published.'" Fulfillium opened the door to the publication inference by indicating in paragraph 43 of its complaint that it was aware of the PMA, which Intersect cited in moving for summary judgment; yet Fulfillium failed to close the door with contrary evidence. In its separate statement opposing summary judgment, Fulfillium "[d]isputed that the FDA published publicly its PMA for the ReShape Duo"; but it provided no evidence to support this statement.

Bare assertions are insufficient to avoid summary judgment. (Sangster v. Paetkau, supra, 68 Cal.App.4th at p. 166.) "[A] party 'cannot avoid summary judgment by asserting facts based on mere speculation and conjecture, but instead must produce admissible evidence raising a triable issue of fact. '" (Dollinger DeAnza Associates v. Chicago Title Ins. Co. (2011) 199 Cal.App.4th 1132, 1144-1145; Code Civ. Proc., § 437c, subd. (d).) An issue of fact is not raised by conclusory assertions. (Brown v. Ransweiler (2009) 171 Cal.App.4th 516, 525.) Fulfillium's suggestion on appeal that publication did not occur in print in the Federal Register in November 2015 is too late; Fulfillium does not (and did not below) deny it learned of the PMA from the FDA's website. Having supplied evidence in paragraph 43 of its complaint that it knew of the PMA, Fulfillium did not provide any evidence in opposing summary judgment to contradict that position.

Fulfillium contends that "even assuming a July 28, 2015 commencement date" for the limitations period, its state court action "was timely . . . because the operative Complaint [it] filed in the Superior Court . . . relates back" to the first federal action it filed in April 2017, which would bring this action within a limitations period commencing with the July 2014 e-mails. We disagree.

"'"Generally, the rules relating to the scope of appellate review apply to appellate review of summary judgments."' [Citation.] 'Though this court is bound to determine whether defendants met their threshold summary judgment burden independently from the moving and opposing papers, we are not obliged to consider arguments or theories . . . that were not advanced by plaintiffs in the trial court.' [Citation.] 'Ordinarily the failure to preserve a point below constitutes a [forfeiture] of the point. [Citation.] This rule is rooted in the fundamental nature of our adversarial system: The parties must call the court's attention to issues they deem relevant. "'In the hurry of the trial many things may be, and are, overlooked which could readily have been rectified had attention been called to them. The law casts upon the party the duty of looking after his legal rights and of calling the judge's attention to any infringement of them.'"' [Citation.] 'Indeed, if this were permitted procedure, parties opposing and losing summary judgment motions could attempt to embed grounds for reversal on appeal into every case by their silence.'" (Meridian Financial Services, Inc. v. Phan (2021) 67 Cal.App.5th 657, 698.)

Perhaps anticipating this conclusion, Fulfillium insists it preserved a relation-back argument below. Its record citation to its opposition papers, however, gives only a procedural history of its federal court action against ReShape, making no reference to the relation-back doctrine it now invokes, including how it might apply to suing a different defendant like Intersect. Fulfillium claims it raised the doctrine at the hearing on the summary judgment motion, but it secured no court reporter for the hearing, and the court in finalizing its settled statement rejected Fulfillium's account of the hearing.

Fulfillium never sought to amend its opposition, leave to reopen, reconsideration of the summary judgment proceedings, or otherwise to timely present a relation-back argument or arguments in the trial court. Intersect therefore had no meaningful opportunity to address the issue. "Considering an issue for the first time on appeal is often unfair to the trial court, unjust to the opposing party, and contrary to judicial economy because it encourages the embedding of reversible error through silence in the trial court." (In re M.H. (2016) 1 Cal.App.5th 699, 713-714.) Because principles of waiver and '"theory of the trial"' apply to summary judgment (North Coast Business Park v. Nielsen Construction Co. (1993) 17 Cal.App.4th 22, 29), we find the relation-back issue forfeited.

The same is true for Fulfillium's equitable tolling claim. Fulfillium asserts it raised the issue below, but provides no record citation. The trial court omitted from its settled statement Fulfillium's proposed language acknowledging that, at the hearing on the summary judgment motion, "Intersect objected to the Court's consideration of Fulfillium's arguments concerning the relation back doctrine and equitable tolling as being outside the scope of its Opposition." Instead, the settled statement the court adopted simply reported the court "had considered the equitable tolling doctrine, but did not think it applied ...."

Earlier, in its summary judgment ruling, the trial court provided some insight into its thinking regarding equitable tolling, which appears to have been sua sponte in the absence of any mention of the issue in Fulfillium's opposition: "It bears repeating that Intersect's alleged misappropriation arises in connection with its alleged formation and management of ReShape, including ReShape's clinical trial(s) and pursuit of FDA PMA approval regarding the subject ReShape device. Plaintiff has not offered evidence showing that Intersect's alleged misappropriation was separate from and/or subsequent to ReShape's alleged misappropriation. As such, the statute of limitations for such alleged misappropriation was not tolled simply by the fact that Plaintiff apparently did not investigate Intersect's involvement until several years after learning of the alleged misappropriation involving the subject ReShape device's clinical trial(s) and pursuit of FDA approval." (Italics added.)

In addition to failing to provide Intersect or the trial court an opportunity to consider specific contentions Fulfillium may have wanted to make concerning the equitable tolling doctrine, on appeal Fulfillium makes no mention of the trial court's ruling. Fulfillium does not challenge the trial court's reasoning, nor suggest that the court made any errors of fact or law related to equitable tolling. Under these circumstances, we decline to wade into the issue for the first time on appeal.

DISPOSITION

The judgment is affirmed. Respondent is entitled to its costs on appeal.

WE CONCUR: MOORE, ACTING P. J., SANCHEZ, J.

Use AI to get other relevant cases.

Comments

Fulfillium, Inc. v. Intersect Partners, LLC
(Jan 3, 2023)